Nasopharyngeal carriage of Streptococcus pneumoniae in children from day-care centers in Smolensk

Clinical Microbiology and Antimicrobial Chemotherapy. 2020; 22(2):149-153

​ Zharkova L.P., Krechikova O.I., Chagaryan A.N., Kozlov R.S.
10.36488/cmac.2020.2.149-153
healthy children day-care centers S. pneumoniae carriage serotypes vaccination
Section
Personal Experience
Type
Original Article
Publication
Clinical Microbiology and Antimicrobial Chemotherapy. 2020; 22(2):149-153

Objective.

To investigate a nasopharyngeal carriage and serotypes of S. pneumoniae in children aged 3 to 6 years from day-care centers in Smolensk.

Materials and Methods.

A total of 245 isolates of S. pneumoniae from 1027 nasopharyngeal swabs from healthy children attending day-care centers was tested. Identification of S. pneumoniae was performed according morphological, cultural and antigenic characteristics (Slidex pneumo-Kit, bioMeriеux, France), susceptibility to optohin and bile. Extraction of S. pneumoniae DNA (338) from nasopharyngeal specimens and cultures was performed using nucleic acids extraction kit AmpliSens® DNA-sorb-В (Interlabservice, Russia). Molecular typing was performed using CDC-recommended PCR method with 22 pairs of primers.

Results.

Children without signs of infection diseases from 14 day-care centers were examined, whose parents have signed an informed consent. There were 245 (24.0%) isolates of S. pneumoniae from 1027 specimens of nasopharynx’s swabs. The partly vaccinated with PCV13 were children aged 3–4 years – 311 (30.3%), in 95 children were healthy carriage (38.2%) of S. pneumoniae. The majority of children under 4 years (716⁄69.7%) were non vaccinated, healthy carriage of S. pneumoniae were 216 (29.3%). The predominant serotypes of S. pneumoniae in partly vaccinated children were: 3 (9.8%), 6AB (17.9%), 19F (13.8%), 11AD (12.2%), 23F (5.3%), 19A (2%), 18ABCF (1.6%), 14 (2%), 9AV (1.2%), 6CD (0.8%). The coincidence of S. pneumoniae serotypes in vaccinated children and included in PCV13 were 54%. The most common serotypes of S. pneumoniae in non-vaccinated children were: 11AD (12.2%), 15A/F (2%), 23A (2%), 22AF (0.4%), 19A (1.3%), 33FA/37 (1.6%) and non-typeable serotypes (27.8%).

Conclusions.

The low coverage of pneumococcal vaccine in children under 6 years shows the initial process of its implementation in Health Care. We detect the reduction of vaccine serotypes in children with incomplete immunization (54%) and notable increase in non-typeable serotypes (27.8%) in nonvaccinated children.

Lyudmila P. Zharkova

Smolensk State Medical University, Smolensk, Russia

Olga I. Krechikova

Institute of Antimicrobial Chemotherapy, Smolensk, Russia

Aida N. Chagaryan

Institute of Antimicrobial Chemotherapy, Smolensk, Russia

Roman S. Kozlov

Institute of Antimicrobial Chemotherapy, Smolensk, Russia

  • 1. WHO. Estimates of disease burden and cost effectiveness. Available at: www.who.int/immunization_monitoring/burden/estimates_burden/en/index.html. Accessed June 19, 2018.
  • 2. Weiser J.N., Ferreira D.M., Paton J.C. Streptococcus pneumoniae: transmission, colonization and invasion. Nat Rev Microbiol. 2018;16:355-367. DOI: 10.1038/s41579-018-0001-8
  • 3. Baranov A.A., Namazova-Baranova L.S., Mayanskiy N.A., Kulichenko T.V., Polunina T.A., Lazareva A.V., et al. Role of Streptococcus pneumoniae in the structure of bacterial infections in the children hospitalized to inpatient hospitals in Moscow in 2011-2012. Pediatricheskaja farmakologija. 2013;10(5):6-12. Russian. DOI: 10.15690/pf.v10i5.816. 612
  • 4. Muravyov A.A., Chagarjan A.N., Bratus E.V., Pertseva T.A., Karpov I.A., Kachankoet E.F. Serological characteristics and antimicrobial susceptibility of Streptococcus pneumoniae isolated from children under 5 years and patients >65 years in Belarus and Ukraine. Klinicheskaja mikrobiologija i antimikrobnaja himioterapija. 2013;15(2):147­-158. Russian.
  • 5. WHO Weekly epidemiological record. 2012;87:129-144. Available at: www.who.int/wer/2012/wer8714/en/.
  • 6. Pilishvili T., Lexau C., Farley M.M., Hadler J., Harrison L.H., Bennett N.M., et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis. 2010;201(1):32-41. DOI: 10.1086/648593
  • 7. Federal Service for Supervision of Consumer Rights Protection and Human Welfare: On the state of sanitary and epidemiological welfare of the population in the Russian Federation in 2017. Available at: www.rospotrebnadzor.ru/upload/iblock/d9d/gd_2017_seb.pdf. Russian.
  • 8. Immunoprophylaxis of pneumococcal infections. Briko N.S., ed. I.M. Sechenov First Moscow State Medical University, Moscow 2013. 250 p. Russian.
  • 9. CDC Streptococcus Laboratory. Available at: www.cdc.gov/streplab/index.html. Accessed June 26, 2014.
  • 10. Feldblum I.V., Semerikov V.V., Golodnova S.O., Nikolenko V.V., Zakharova Y.A., Vorobyeva N.N. Results of serotyping of Str. pneumoniae strains circulating in Perm. Zdorov’e sem’i – 21 vek. 2013;2(15):194203.
  • 11. Baranov A.A. Streptococci and pneumococci. Rostov-on-Don: Feniks, 2013. 301 p. Russian.
  • 12. Andrews N.J., Waight P.A., Burbidge P., Pearce E., Roalfe L., Zancolli M., et al. Serotypespecific effectiveness and correlates of protection for the 13valent pneumococcal conjugate vaccine: a post licensure indirect cohort study. Lancet Infect Dis. 2014;14(9):839­ 846. DOI: 10.1016/S1473-3099(14)70822-9
  • 13. Waight P.A., Andrews N.J., Ladhani S.N., Sheppard C.L., Slack M., Miller E. Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study. Lancet Infect Dis. 2015;15(6):629. DOI: 10.1016/S1473-3099(15)70044-7
Views
0 Abstract
0 PDF
0 Crossref citations
Shared